EMEA-002989-PIP01-21
Key facts
| Active substance |
Leniolisib
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0556/2021
|
| PIP number |
EMEA-002989-PIP01-21
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Pharming Group N.V.
Tel. +31 715247400
E-mail: info@pharming.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|